Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive
  • Overview
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2005

Search

Here you find Investor News of year 2005. Ad-hoc messages issued in year 2005 can be found here.

Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR news via E-Mail, RSS Feed or SMS.

Tuesday December 20, 2005

New treatment for advanced renal cell carcinoma:

Anticancer drug Nexavar® granted U.S. approval

Approval faster than expected / Major milestone for Bayer oncology franchise / Shipment to pharmacies within the next 24 hours

Wednesday December 14, 2005

Dr. Wolfgang Plischke appointed to the Bayer Management Board

Dr. Gunnar Riemann to head the Pharmaceuticals Division / Peter Nicklin to take charge of the Animal Health Division

Tuesday December 13, 2005

47th Annual Meeting of the American Society of Hematology:

Novel, oral Factor Xa inhibitor (BAY 59-7939): Positive results of Phase II once-daily study presented

10 mg once-daily dose to be studied in Phase III clinical trials for prevention of venous thromboembolism (VTE)

Monday December 12, 2005

Landmark Study Demonstrates Benefits of Prophylactic Treatment Regimen in Hemophilia A

Results from Multi-year Clinical Trial Shows Improved Joint Outcomes in Young Children Using Kogenate® FS

Thursday December 08, 2005

Bayer Launches Phase III Clinical Study of Trasylol® in Elective Spinal Fusion Surgery

Study Examines Effects of Trasylol in Reducing Bleeding and Need for Blood Transfusions for Spinal Fusion Patients

Thursday December 08, 2005

Investor conference in London on research and development:

Wenning: “We have great confidence for the future”

Phase III study with Nexavar® to treat lung cancer / Oral thrombosis drug entering Phase III with once-daily dose / Sales forecasts raised for Kogenate® and Trasylol® / New CropScience active ingredients have sales potential of EUR 2 billion / MaterialScience a global trendsetter in plant capacity and process efficiency

Tuesday December 06, 2005

Bayer creates a provision in the amount of 275 million euros for civil antitrust actions

Wednesday November 30, 2005

Avelox® Approved in US to Treat Complicated Intra-abdominal Infections

Once-a-day Dosage Offers Effective and Convenient Treatment Option

Monday November 28, 2005

Bayer HealthCare Receives FDA Approval for Kogenate® FS with BIO-SET®

Innovative reconstitution system will offer safety and simplicity for people living with hemophilia A

Wednesday November 16, 2005

Bayer MaterialScience increases prices for HDI and HDI-based aliphatic isocyanates

Wednesday November 09, 2005

Fall Financial News Conference of Bayer AG

Bayer boosts third-quarter earnings: operating result doubled

Third-quarter sales up 19.1 percent to EUR 6,531 million / Strong gains by all subgroups / Group net income up from EUR 52 million to EUR 493 million / Guidance raised again: full-year underlying EBIT expected to increase by about 50 percent

Thursday November 03, 2005

Bayer HealthCare: Majority holding in anti-infectives research acquired by Santo Holding AG

Jobs in Wuppertal to remain / closing expected in 1st quarter of 2006

Thursday November 03, 2005

Bayer HealthCare: Majority holding in anti-infectives research acquired by Santo Holding AG

Jobs in Wuppertal to remain / closing expected in 1st quarter of 2006

Thursday November 03, 2005

Investigator Presents Update on Phase III Sorafenib Trial in Patients with Advanced Kidney Cancer

Thursday November 03, 2005

Investigator Presents Update on Phase III Sorafenib Trial in Patients with Advanced Kidney Cancer

Wednesday October 26, 2005

Cooperation for Factor Xa-Inhibitor, BAY 59-7939:

Bayer HealthCare and Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson Company, Announce Collaborative Development and License Agreement for Antithrombosis Drug

U.S. marketing rights to Ortho-McNeil for cardiology, primary care and hospital segments / Co-promotion agreement for marketing of Ortho-McNeil drug Elmiron® by Bayer HealthCare to the urology audience

Friday October 21, 2005

Bayer wins approval for Avelox® (Moxifloxacin) in Japan

- Shionogi & Co. Ltd. has exclusive marketing rights / Japan is the world’s second largest pharmaceutical market

Thursday October 20, 2005

Window is opening for polycarbonate automobile window glazing

US Department of Transportation confirms that Exatec® 900 window glazing system can be used in the USA

Thursday October 06, 2005

Bayer ceases bidding for Boots OTC business

Friday September 30, 2005

Dr. Derek W. Gilroy receives International Aspirin® Award

New mechanism of action of Aspirin discovered

The active ingredient of Aspirin® stimulates the production of nitric oxide, thereby inhibiting inflammation

Monday September 19, 2005

Trasylol (Aprotinin Injection) Reduced Bleeding and Transfusion Requirements in Patients on Clopidogrel who Required Coronary Artery Bypass Graft (CABG) Surgery

New study addresses critical days prior to CABG surgery when stopping antiplatelet therapy may delay operation and expose patients to risk of cardiac events

Wednesday September 14, 2005

Bayer and Onyx Announce FDA Acceptance of New Drug Application for Sorafenib for Individuals with Advanced Renal Cell Carcinoma

Priority Review Designation Granted

Monday September 12, 2005

Bayer and Onyx Announce European Marketing Submission for Sorafenib

European Trial to Provide Access to Sorafenib for Individuals with Advanced Renal Cell Carcinoma

Monday September 05, 2005

"Analyst and Investor Days 2005" in Lyon:

Bayer CropScience: Sales of new products should rise to € 2 billion

Company counting on its first-class product pipeline

Wednesday August 10, 2005

Bayer interim report:

Dynamic sales and earnings growth continues in the second quarter

Sales rise 20 percent to over EUR 7 billion / EBIT before special items up 39 percent / Group net income almost tripled to EUR 406 million / Significant increase in guidance for 2005 sales and underlying EBIT / About 40 percent growth in underlying EBIT predicted for 2005

Monday August 08, 2005

XXth Congress of the International Society on Thrombosis & Haemostasis (ISTH):

Promising Safety and Efficacy Results of BAY 59-7939 Phase II Studies Pave the Way for Phase III Clinical Program to Begin this Year

Tuesday July 19, 2005

Enormous interest from investors

Bayer successfully completes refinancing

EUR 1.3 billion hybrid bond issued / Bayer repurchases bonds with a face value of around EUR 860 million

Tuesday July 19, 2005

Two Phase-II studies indicate that oral BAY 59-7939 is safe and effective in preventing venous thromboembolism

Monday July 11, 2005

Bayer and Onyx Complete Filing of New Drug Application for Sorafenib for Individuals with Advanced Renal Cell Carcinoma

Thursday July 07, 2005

Bayer repurchases part of Eurobond issue and launches new hybrid bonds

Friday July 01, 2005

Increased transparency in drug development:

Bayer HealthCare posts information on clinical trials on the Internet

Thursday June 30, 2005

Bayer presses ahead with investment projects in China:

First stage of major polycarbonate project inaugurated

Go-ahead for construction of a world-scale MDI plant with a capacity of 350,000 tons/year / Global MDI capacity to be increased to 1.3 million tons/year

Wednesday June 29, 2005

Innovative liposome technology

Bayer Completes Investigational New Drug filing with FDA For Longer-Acting Kogenate® Product

Company ready to begin Phase I clinical trials with hemophilia A patients

Monday June 06, 2005

Bayer sells mandatory convertible bond back to Lanxess

Tuesday May 24, 2005

Bayer MaterialScience closes TDI Facility at New Martinsville

Saturday May 14, 2005

Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006) for Individuals with Advanced Renal Cell Carcinoma

Treatment Protocol has been Reviewed by FDA

Saturday May 14, 2005

Sorafenib (BAY 43-9006) Doubles Progression-Free Survival in Phase III Kidney Cancer Trial

Independent Assessment Shows Median Progression-Free Survival of 24 Weeks

Friday May 13, 2005

Bayer and Onyx Initiate Phase III Metastatic Melanoma Trial Administering Sorafenib (BAY 43-9006) in Combination with Chemotherapy

Thursday May 12, 2005

Bayer CropScience plans further profitable growth:

Sales of new active ingredients to reach EUR 1 billion, EBITDA margin to improve to 25 % by 2006

Innovative products to offer new solutions for farmers, drive company growth

Tuesday May 10, 2005

Existing plants expanded and investment in China accelerated:

Bayer MaterialScience significantly increases Makrolon® production

1,000,000 tons capacity expected by end of 2005, further expansion on the horizon

Tuesday May 10, 2005

Bayer Group interim report:

Sales and earnings advance strongly in first quarter

- 2005 guidance for Bayer HealthCare increased / - Full-year Group forecast confirmed

Wednesday May 04, 2005

Sorafenib (BAY 43-9006) Accepted into FDA Pilot 1 Program

Friday April 29, 2005

Bayer MaterialScience to participate in the development of holographic storage media

Opening up a new dimension

Cooperation agreement signed with high-tech US company / Aim is for storage media with a capacity of up to 1.6 terabytes / Highly promising market for Bayer MaterialScience's polymer raw materials

Friday April 29, 2005

Werner Wenning at the Annual Stockholders’ Meeting in Cologne:

Bayer’s earnings advance strongly in first quarter

- Underlying EBIT from continuing operations up by 50.1 % to EUR 1,142 million / - Full-year 2005 forecasts confirmed / - Wenning calls for R& D commitment by politicians

Tuesday April 19, 2005

Bayer CropScience announces supply agreement for Imidacloprid with Cheminova

Tuesday April 19, 2005

Bayer CropScience and Makhteshim Agan sign multi-year non-exclusive supply agreement for Imidacloprid

Monday April 18, 2005

Bayer and Onyx Unblind Patients In Ongoing Sorafenib Phase III Clinical Trial In Advanced Renal Cell Carcinoma

Independent Committee Endorses Company Decision To Offer All Patients Active Drug

Monday April 11, 2005

Bayer Initiates Phase III Clinical Study of Trasylol® Therapy During Primary Total Hip Replacement Surgery

Study Examines the Effects of Trasylol in Reducing Blood Loss and the Need for Transfusion

Friday April 01, 2005

Bayer completes transaction involving plasma business

Kogenate® product line remains in Bayer HealthCare portfolio

Monday March 21, 2005

BAY 43-9006 Shown to Delay Disease Progression in Phase III Study in Advanced Kidney Cancer Patients

Study met surrogate endpoint

Tuesday March 15, 2005

Werner Wenning at the Spring Financial News Conference on March 15:

Bayer expects considerable growth in sales and earnings from continuing operations in 2005

- Adjusted EBIT from continuing operations to increase by some 20 percent / - Encouraging figures for January and February / - All subgroups contribute to successful performance in 2004 / - Strategic realignment of the Bayer Group completed

Tuesday March 08, 2005

Bayer and Onyx Announce Initiation of Phase III Clinical Trial of BAY 43-9006 in Patients with Advanced Primary Liver Cancer

Wednesday March 02, 2005

Provisional figures for fiscal 2004:

Bayer significantly improves both sales and earnings

- Currency- and portfolio-adjusted sales rise by 9 percent / - EBIT before special items up 53 percent to EUR 2.2 billion / - Management Board proposes dividend of EUR 0.55 per share for 2004

Wednesday February 23, 2005

Advisory Panel Discussion points to Aleve®

Members of FDA Committees Support Safety of Naproxen, Active Ingredient in Aleve®

Friday February 04, 2005

Bayer CropScience, Max Planck Society and Monsanto Company resolve Agrobacterium patent dispute

Thursday February 03, 2005

Bayer CropScience CEO Prof. Dr. Friedrich Berschauer in Brazil:

Bayer CropScience intends to further expand its market leadership position in Latin America

Sales in Latin America rise 32 % in the first nine months of 2004

Friday January 28, 2005

Entry in the Bayer AG commercial register:

Lanxess spin-off accomplished

Tuesday January 18, 2005

Lanxess Listing Memorandum to be published on January 19

Thursday January 13, 2005

U.S. EPA grants approval for use of Bayer CropScience’s Stratego fungicide to control Asian soybean rust

Monday January 10, 2005

GSK’s Levitra Co-Promotion Rights Transferred Back to Bayer in Most Major Markets Outside the U.S.

Saturday January 01, 2005

Deal successfully closed and Roche Consumer Health business now integrated

Bayer Consumer Care Operates combined Business January 1

Division ranks among the top three OTC players – Supradyn®, Redoxon®, Bepanthen®, and Rennie® are now in the Bayer family of brands